The sub-group analysis of cancer stage, ethnicity, sex, age, weight, tumor grade, and TP53 mutation showed that the expression of RAB22A in HCC patients was significantly higher than that in the normal group (Figures 2B–H). This evidence concerns the gene TP53 and hepatocellular carcinoma.